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ABSTRACT
Ovarian cancer presents as an aggressive, advanced stage cancer with widespread 
metastases that depend primarily on multicellular spheroids in the peritoneal fluid. 
To identify new druggable pathways related to metastatic progression and spheroid 
formation, we integrated microRNA and mRNA sequencing data from 293 tumors 
from The Cancer Genome Atlas (TCGA) ovarian cancer cohort. We identified miR-
509-3p as a clinically significant microRNA that is more abundant in patients with 
favorable survival in both the TCGA cohort (P = 2.3E–3), and, by in situ hybridization 
(ISH), in an independent cohort of 157 tumors (P < 1.0E–3). We found that miR-509-
3p attenuated migration and disrupted multi-cellular spheroids in HEYA8, OVCAR8, 
SKOV3, OVCAR3, OVCAR4 and OVCAR5 cell lines. Consistent with disrupted spheroid 
formation, in TCGA data miR-509-3p’s most strongly anti-correlated predicted targets 
were enriched in components of the extracellular matrix (ECM). We validated the 
Hippo pathway effector YAP1 as a direct miR-509-3p target. We showed that siRNA 
to YAP1 replicated 90% of miR-509-3p-mediated migration attenuation in OVCAR8, 
which contained high levels of YAP1 protein, but not in the other cell lines, in which 
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levels of this protein were moderate to low. Our data suggest that the miR-509-
3p/YAP1 axis may be a new druggable target in cancers with high YAP1, and 
we propose that therapeutically targeting the miR-509-3p/YAP1/ECM axis may 
disrupt early steps in multi-cellular spheroid formation, and so inhibit metastasis 
in epithelial ovarian cancer and potentially in other cancers.
INTRODUCTION
Epithelial ovarian cancer (EOC) is the most lethal 
gynecological malignancy, typically presenting as an 
aggressive, advanced stage cancer with widespread 
metastases in the peritoneum [1]. It metastasizes 
primarily by cells exfoliating into the peritoneal fluid, and 
aggregating into multicellular spheroids that invade the 
peritoneal membrane [2, 3] and can resist chemotherapy 
[4–6]. While patients typically respond initially to 
cytoreductive surgery and to platinum- and taxane-
based chemotherapy, most develop relapsed disease that 
becomes refractory to all current therapies. There is a 
pressing need for new therapeutic strategies that sensitize 
these cancers to current therapies. 
Recently, The Cancer Genome Atlas (TCGA) 
Research Network characterized 489 high-grade serous 
ovarian cancer (HGSOC) tumors [7], using microarrays 
for gene and microRNA expression. Here, we report 
results from 293 TCGA ovarian tumors, using messenger 
RNA (mRNA) and microRNA (miRNA/miR) sequencing 
data. miRNAs are ~22-nucleotide non-coding RNAs that 
regulate transcript stability and translation, primarily 
by binding sites in 3′-UTRs [8]. We anticipated that the 
sequencing data could yield new insights by offering 
a wider dynamic range than microarrays, higher spatial 
resolution and sensitivity, isoform-specific mRNA 
expression, and better discrimination between miRNA 
stem-loops and mature miRNA strands [9]. 
We identified the X-linked miR-509-3p as a 
clinically significant miRNA. The miR was more abundant 
in patients with favorable survival in both the TCGA and 
an independent cohort. In attenuated migration, invasion, 
and aggregation into three-dimensional (3D) spheroids 
in the six ovarian cancer cell lines tested: HEYA8, 
OVCAR8, SKOV3, OVCAR3, OVCAR4 and OVCAR5. 
We showed that YAP1, a key oncogene in a subset of 
ovarian and other cancers, is a direct downstream target 
of miR-509-3p. We also found that siRNA to YAP1 was 
necessary and sufficient to replicate ~90% of miR-509-
3p-mediated attenuation of migration in OVCAR8, which 
contained high levels of YAP1 protein. However, siYAP1 
had no impact on migration attenuation or multi-cellular 
spheroids in the other cell lines, suggesting that the miR-
509-3p/YAP1 axis is relevant only in cells containing high 
YAP1. 
Since miR-509-3p’s strongest anti-correlated 
predicted targets in TCGA ovarian tumors were enriched 
for components of the extracellular matrix (ECM), and 
effects on ECM components are consistent with effects on 
3D spheroid formation, we propose that miR-509-3p may 
act in ovarian cancers by targeting both ECM components 
and YAP1. We anticipate that the miR-509-3p/YAP1/
ECM axis offers a novel therapeutic focus for controlling 
metastatic progression in HGSOC.
RESULTS
An independent component that discriminates 
overall survival is enriched in Xq27.3 miR cluster 
members, and in ECM and cell adhesion genes
We identified mRNA transcript isoforms from the 
mRNA-seq data using reference-based assembly [10], 
and calculated TargetScan 6.0 [11] miRNA binding sites 
on the full length reconstructed transcripts. For the 293 
tumor samples with both mRNA-seq and miRNA-seq data 
(Table S1), we identified anti-correlated miRNA:mRNA 
pairs by calculating Spearman correlation coefficients (r) 
between the abundance profiles for mRNA isoforms and 
for 5p and 3p miRNA strands, thresholding at a q-value 
(FDR) < 0.05 (Table S2). Consistent with previous work 
[12], the miR-9 family and miR-29a/b were important 
for interactions with correlations below –0.3. Stronger 
interactions were also enriched in members of a ~100-kb 
cluster in Xq27.3 that contains hsa-mir-506, 507, 508, 509, 
510, 513 and 514 (Figures 1A to 1C, and S1A), particularly 
for miR-506, miR-508, miR-509, miR-513 and miR-514. 
For the 250 target genes with the strongest anti-correlations 
to members of this cluster, enriched Gene Ontology terms 
highlighted the ECM, and enriched KEGG pathways 
included ECM-receptor interactions (FDR = 6E–8) 
and focal adhesion (FDR = 0.02) (Table S3). 
We extended these results by using independent 
component analysis (ICA) [13] to retrieve significant 
associations between miRNAs, mRNAs, and pathways. 
ICA is robust to co-expressed genes that are not always 
co-regulated [14], and to anti-correlations between 
miRNAs and target mRNAs that are not always significant 
[15]. Independent components (ICs) have been shown to 
capture the differential regulation of biological processes 
and metabolic pathways in breast cancer [16], acute 
myeloid leukemia [17], and Alzheimer’s disease [18]. 
Briefly, ICA linearly decomposes an expression 
matrix (E) into ICs by solving the matrix equation E = CM. 
The columns of the component matrix C are the ICs in 
which each gene has a weight, and the weight of each IC in 
the samples is contained in the rows of the mixing matrix 
M. For miRNA-mRNA interactions, the gene weights of 
targeted mRNAs should be inversely correlated with the 
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Figure 1: Significant miRNAs, mRNAs and pathways. (A) Schematic transcriptome-wide view of the number of significant (FDR 
< 0.05) anti-correlations per miRNA (Spearman r < –0.3, for miRNAs with at least one significant anti-correlation). miRNA locations are 
not to scale. (B) The miRNAs in (A), ordered by the number of miR-gene interactions, and thresholded at 20 interactions. (C) miR-gene 
interactions with Spearman correlation coefficients less than –0.5. (D–G) Independent component analysis. (D) Kaplan-Meier plot for 
overall survival when samples are segregated by high vs. low component weights in IC 5 (see text). (E) Component weights of IC 5, for 
samples with favorable vs. unfavorable survival, for the mixing matrices for mRNAs (left) and miRNAs (right). Because samples with 
favorable survival have larger component weights than samples with favorable vs. unfavorable survival in IC 5, mRNAs with negative gene 
weights in this IC will be downregulated in samples with favorable survival. (F) Gene weights and q-values for the mRNAs and miRNAs 
that have significant gene weights in IC 5 (thresholds α = 6 for mRNAs, 1 for miRNAs) and are differentially expressed between samples 
with favorable and unfavorable overall survival. Green vs. orange: upregulated vs. downregulated in samples with favorable survival. (G) 
Enriched GO terms and pathways for IC 5 genes (q < 0.001, hypergeometric test, FDR-correction). R and K indicate REACTOME and 
KEGG, respectively.
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gene weights of targeting miRNAs in an IC that captures 
regulation by miRNAs. To identify such anti-correlations 
we modified the R function fastICA, which is widely used 
for expression data [19]. The resulting method, miICA, 
considers mRNA and miRNA data simultaneously. 
ICA returned five ICs (Table S4). Using each 
IC’s component weights, i.e. the rows of Mm and Mmi, 
we divided the samples into groups with favorable vs. 
unfavorable survival or recurrence by identifying an 
optimal component weight threshold for a two-group 
Kaplan-Meier test (K-M test) against clinical outcomes 
[20]. IC 5 best discriminated samples by survival 
(P = 2.3E-3, Figures 1D, S1B and S1C). IC 5′s component 
weights were higher in samples with favorable survival 
(Figure 1E, K-W test, FDR correction), which means that 
mRNAs or miRNAs with positive gene weights in this 
component were more abundant in the group of samples 
with favorable survival (Figures 1C and S1D). IC 5 
contained 65 mRNAs with very significant gene weights 
(Figure 1F, α = 6), all of which were also differentially 
expressed between samples with favorable and unfavorable 
survival (q < 0.05, K-W test, FDR correction). Since 
miRNAs generally had lower gene weights than mRNAs 
in IC 5, we used a lower threshold α cut-off (α = 1) to 
identify 62 miRNAs with significant gene weights in IC 
5, 24 of which were also differentially expressed between 
samples with favorable and unfavorable survival (Figures 
1F and S1D, q < 1.0E-2, K-W test, FDR correction). 
miRNAs from the Xq27.3 miR cluster were more abundant 
in samples with favorable survival and had positive gene 
weights in IC 5; thus, targets of these miRs that are relevant 
to HGSOC should be sought among mRNAs with negative 
gene weights in this IC.
Consistent with the correlation analysis, many of the 
most significantly enriched pathways for IC 5 (Figure 1G) 
involve genes related to the ECM and cell adhesion 
(Table S4, threshold α = 3, q < 1.0E-3, K-W test). In all 
of these pathways the majority of genes had negative gene 
weights that were anti-correlated with the IC 5 gene weights 
of members of the Xq27.3 miR cluster. Predicted targets 
of the cluster miRs were significantly overrepresented 
among genes with negative gene weights in IC 5 (Table S4), 
consistent with targets of the miR cluster being associated 
with the enriched pathways. Overall, these results indicate 
that members of the Xq27.3 miR cluster, and the significant 
genes from IC 5 that are annotated as members of significant 
pathways, may be associated with survival in HGSOC.
The Xq27.3 miRNA cluster is predicted to target 
structural and regulatory ECM components, and 
EMT regulators
To characterize in more detail ECM components 
that may be targeted by miR cluster members, we 
compared 1368 predicted target genes, and the 541 
significant IC 5 genes, to six functional groups that 
have been defined for core matrisome and ECM-
associated genes [21] (Table S5). For the core matrisome, 
predicted targets included 38 of 200 glycoproteins 
(P = 5.3E-10), 17 of 45 collagens (P = 6.2E-10) and 14 of 
36 proteoglycans (P = 1.3E-8). For ECM-affiliated genes, 
predicted targets included 23 of 177 affiliated proteins 
(P = 6.7E-4), 51 of 254 regulators (P = 8.0E-14), and 
50 of 353 secreted factors (P = 4.8E-8). Similarly, IC 5 
genes were enriched in all ECM functional gene groups 
(P = 6.6E-24 to 6.6E-8) except ECM-affiliated genes. 
We then assessed ECM-rich gene sets [22] that were 
prognostic for overall survival or recurrence in microarray-
based gene expression data from the original TCGA study 
and two independent studies [7, 23, 24]. We compared six 
sets of highest-ranked 100 genes from: a) networks based 
on co-expression, functional linkage, and L2 penalty, and 
b) survival and recurrence outcomes, to the functional 
ECM groups, predicted miR cluster targets, and IC 5 
genes (Table S5). The six gene sets were typically enriched 
(P < 0.001) for ECM glycoproteins, collagens, regulators 
and secreted factors. The 1368 predicted miR cluster 
targets were enriched in the gene sets for overall survival 
(P = 4.2E-52 to 1.3E-22) and for recurrence (P = 1.2E-33 
to 1.4E-12). Finally, the 541 IC 5 genes were enriched in 
all six prognostic gene sets (P = 1E-25 to 3E-80). 
Our sequencing data also identified epithelial-
mesenchymal transition (EMT) regulators [25] as 
predicted targets of members of the miR cluster and of 
the miR-200 family: SNAI1 (miR-510-5p), SNAI2 (miR-
507, miR-200b-3p), TWIST1 (miR-507, 508-3p, 509-3p), 
TWIST2 (miR-141-3p, 29b-3p, 29c-3p), ZEB1 (miR-141-
3p, 200b-3p) and ZEB2 (miR-200b-3p, 507, 508-5p and 
3p, 513c-5p, 514b-5p). Significant IC 5 genes included 
SNAI2, TWIST1, TWIST2 and ZEB1 (Table S2). 
Given these results, we assessed how miR-509-3p 
mimics influenced levels of transcripts associated with 
ECM and EMT in TP53-wild type HEYA8 and TP53-
mutated OVCAR8 ovarian cancer cell lines, in which we 
carried out time-series qPCRs on selected genes. TaqMan 
assays confirmed that miR-509-3p increased ~10,000 
fold in abundance at 72, 96 and 120 h following transient 
transfection of miR-509-3p mimics (Figure S3A). Of 
the ECM and cytoskeletal genes, ACTA2, COL1A1 and 
COL3A1 were downregulated in response to miR-509-
3p mimics in both cell lines at 72, 96 and 120 h after 
transfection, which correspond to 0, 24 and 48 h time 
points of the migration/invasion experiments (Figure S3B 
to S3D). Treatment with miR-509-3p mimics resulted 
in COL5A1 downregulation in HEYA8 but upregulation 
in OVCAR8, while COL5A2 was not significantly 
affected by the mimic in HEYA8, and was not detected 
in OVCAR8. ECM genes SPARC, FN1 and PRRX1 were 
upregulated in response to miR-509-3p mimics in both cell 
lines. miR-509-3p mimics downregulated TWIST at all 
three time points in both cell lines, and more significantly 
in HEYA8 than in OVCAR8 at each time point. SNAI2 
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was upregulated at all three time points in both cell lines, 
with fold changes generally more significant in OVCAR8 
than in HEYA8. 
miR-509-3p is positively associated with clinical 
outcomes and is localized to tumor cells
For members of the Xq27.3 miR cluster, and the 
miR-29 and miR-200-families, we identified compact 
subsets of miRNA 5p and 3p strands whose abundance 
discriminated overall survival or time to recurrence. After 
correcting for multiple testing, only miRs from the Xq27.3 
cluster remained statistically significant. For example, 
miR-506, 507, 508 and 509 collectively stratified a group 
of 37 samples by overall survival (P < 0.049) (Figures 2A, 
2B and S2; Table S6). 
From computational results, and the migration/
invasion results described below, we focused on miR-
509-3p. To confirm miR-509-3p’s association with overall 
survival, and to determine whether the miR was expressed 
by cells within the tumor and/or the stromal cells from the 
tumor microenvironment, we used in situ hybridization to 
stain tissue microarrays for miR-509-3p in an independent 
set of 157 HGSOC samples (Table 1). We scored staining 
intensity in high-powered image fields in a blinded 
fashion by quantitative image analysis with CellProfiler 
v2.0 [26]. Consistent with results from sequencing data, 
overall survival was favorable (P < 1.0E-3) for samples 
with higher miR-509-3p expression levels (Figure 2C); 
progression-free survival was also favorable (P < 1.0E-3, 
Figure 2D). When miR-509-3p was detected, we found that 
it was largely localized within the tumor cells and not in the 
stroma (Figure 2E and 2F). 
However, the ovarian cancer cell lines we tested had 
relatively low levels of miR-509-3p expression by qPCR 
(Figure S4A). The microarray-based miRNA abundance 
data in the NCI-60 cell lines (GEO: GSE26375) [27] 
includes seven ovarian cell lines (IGROV1, NCI/ADR-
RES, OVCAR-3, OVCAR-4, OVCAR-5, OVCAR-8, 
SK-OV-3), five of which are included in the work that we 
report here. In these data too, the expression of miR-509-
3p is low compared to other microRNAs such as miR-
29abc and members of the miR-200 family (Figure S4B 
and S4C). 
miR-508-3p and miR-509-3p attenuate ovarian 
cancer cell migration and invasion
Because miR-508 and miR-509 were correlated 
with overall survival, and had predicted targets that were 
enriched for ECM components and for EMT regulators, 
we hypothesized that these miRNAs may be able to 
Figure 2: miR-509-3p and clinical outcomes. (A, B) Kaplan-Meier plots for overall survival and time to recurrence for a discriminatory 
subset of Xq27.3 miRs, from TCGA sequencing data. (C, D) For an independent set of HGSOC samples, Kaplan-Meier plots for overall 
survival (N = 157) and progression-free time (N = 140) for sample groups separated by the median miR-509-3p in situ hybridization (ISH) 
score. (E, F) Representative ISH micrographs for miR-509-3p, showing (E) high (291) and (F) low (0) ISH staining intensities. Black and 
grey arrows indicate tumor and stroma cells respectively. Scale bars are 100 um.
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influence clinical outcomes in HGSOC by attenuating 
migration and invasion, and so metastatic progression. 
We assessed this in vitro, using a 96-well scratch-wound 
assay to compare HEYA8 and OVCAR8 cells that were 
untreated, versus those treated with either miRNA mimics 
from the Xq27.3 miR cluster or with a scrambled negative 
control (SCR) sequence. 
Transient transfection with miR-509-3p strongly 
attenuated the ability of cells to migrate (Figure 3A and 3C) 
and invade a Matrigel matrix in both cell lines (Figure 3B 
and 3D). The relative wound density (RWD) of migration 
at 24 h was 39% lower in HEYA8 (p53-wild type) 
(P = 5.3E-13) and 64% lower in OVCAR8 (p53-mutant) cells 
(P = 5.8E-13) than in the same cells treated with the 
scrambled negative control sequence. Transient transfection 
with miR-508-3p had a smaller effect on migration for 
HEYA8 cells (6.3% reduction in RWD at 24 h, P = 0.20), 
and an intermediate effect in OVCAR8 cells (25% 
reduction in RWD at 24 h, P = 5.8E-13).  In contrast, 
miR-509-5p only slightly reduced migration, as shown 
by the 11% decrease in RWD at 24 h for OVCAR8 cells 
(P = 6.6E-4), and showed no significant effect in HEYA8 
(P = 1.00). The ability of cells to invade a Matrigel 
matrix was also most strongly attenuated by miR-509-
3p, with a 70% reduction in RWD for HEYA8 (P = 
5.4E-13), and a 29% reduction in OVCAR8 compared 
to SCR (P = 3.0E-3). miR-508-3p also reduced invasion, 
as indicated by the 6% decrease in RWD for HEYA8 
(P = 1.9E-3) and 18% in OVCAR8 (P = 1.3E-2) and miR-
508-5p did not significantly affect invasion for OVCAR8 
(P = 0.89) or HEYA8 cells (P = 0.15). In contrast, miR-
509-5p reduced invasion in OVCAR8 (14% reduction in 
RWD at 24 h, P = 3.2E-6), but did not significantly affect 
migration in HEYA8 cells (P = 1.0).
In independent experiments, we confirmed that 
miR-509-3p mimics attenuated migration strongly in 
OVCAR8 and SKOV3 and moderately in OVCAR3, 
OVCAR4, OVCAR5 and HEYA8 (Figures 5A, S5). Since 
the basal level of miR-509-3p in cells was very low in 
all six ovarian cancer cell lines tested (Figure S4A), the 
miR-509-3p inhibitor did not affect migration in these cell 
lines (Figure 6A).
miR-509-3p influences transcript levels of genes 
involved in migration and invasion, and directly 
targets YAP1 
We identified which of 143 miR-509-3p target 
genes predicted by TargetScan v6.2 (www.targetscan.
org) have been reported as involved in cellular migration 
and invasion, then used quantitative RT-PCR with gene-
specific primers to evaluate transcript levels for the 
predicted targets BCAR1 [28], GPC6 [29], KCNMA1 [30], 
PBX3 [31], and YAP1 [32, 33]. Cells transfected with 
miR-509-3p mimics showed strong down-regulation of 
four of the five genes in OVCAR8 cells and three of the 
five genes in HEYA8 cells, relative to SCR treated and 
untreated controls (Figure S3E and S3F). Because YAP1 
is an oncogene in ovarian cancer, and a high YAP1 level 
is associated with poor ovarian survival in TCGA data 
(Figure 4F), our independent cohort of 157 patients and 
in an independent study [34], we characterized YAP1 in 
more detail. 
YAP1 is a transcriptional co-activator and key 
downstream nuclear effector of the Hippo signaling 
pathway [32, 33]. YAP1 protein level was downregulated 
in response to miR-509-3p mimics in both HEYA8 and 
OVCAR8 cell lines at 72, 96 and 120 h after transfection 
(Figure S3G). To demonstrate that the gene is a critical 
downstream mediator of miR-509-3p, we first showed that 
the downregulation seen from qPCR, Western blots and 
immunofluorescence staining (Figure 4A, 4B and 4E) is 
due to direct repression through one or both of the two 
predicted miR-509-3p binding sites in the YAP1 3′ UTR 
(Figure 4C). In luciferase reporter assays, both predicted 
target sites responded independently to miR-509-3p 
mimics (Figure 4D), and a mutation at either site was 
sufficient to abrogate miR-509-3p-mediated repression of 
Table 1: Summary of independent HGSOC cohort used for ISH
miR-509-3p
Variable Low (N = 75) High (N = 82) P-value
Tumour stage I or II 4 9 0.21
III or IV 70 73
Cytoreduction Optimal 41 56 0.11
Suboptimal 30 24
Recurrence or progression Yes 57 57 3E-2
No 8 21
Median PFS (yr) 7.7 21.3 < 1.0E-3
Median OS (yr) 40 81.2 < 1.0E-3
For miR-509-3p, low and high refer to ISH staining intensities that are below and above the median intensity.
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the reporter. Then, we confirmed that low YAP1 abundance 
was associated (P = 0.018) with better survival in the 
TCGA cohort (Figure 4F) [20]. Finally, we found that 
siRNA to YAP1 impaired migration approximately 90% 
in OVCAR8 as effectively as miR-509-3p (Figure 5A). 
However, siYAP1 had no observable effect on migration 
in HEYA8 (Figure 5A), SKOV3, OVCAR3, OVCAR4 
and OVCAR5 (Figure 6A). Our qPCR and Western blots 
showed that miR-509-3p repression on YAP1 was largely 
at the protein rather than the transcript level (Figure 4A, 
4B and Figure S6A, S6B). We also found that the level of 
YAP1 protein was over 2.4 fold higher in OVCAR8 than 
in HEYA8, SKOV3, OVCAR3, OVCAR4 and OVCAR5 
(Figure S6C). Consistent with this, miR-509-3p had the 
largest influence on cellular migration in OVCAR8, and 
only marginal influence in the other cell lines, all of which 
expressed moderate to low levels of YAP1. We performed 
a rescue experiment to show that overexpression of 
exogenous YAP1 largely reversed the inhibitory effects of 
miR-509-3p on migration in OVCAR8 cells. OVCAR8 
cells co-transfected with a miR-509-3p mimic and a YAP1 
overexpression plasmid (pCDNA-FLAG-YAP1) had 
migrated 158% faster at 40 h than cells co-transfected 
with a miR-509-3p mimic and an empty vector C-FLAG-
pCDNA3 (P = 0.040) (Figure S7). These data suggests that 
YAP1 is likely an important prognostic marker for EOC and 
that miR-509-3p/YAP1 axis may provide new druggable 
targets for ovarian tumors with high levels of YAP1.
Figure 3: In vitro 96-well migration and invasion results after transfecting miR mimics into HEYA8 and OVCAR8 
cells. (A) Migration and (B) invasion for HEYA8 cells (N = 3). (C) Migration and (D) invasion for OVCAR8 cells (N = 3). Error bars show 
standard deviations. The time courses start 72 h after transfection. 
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miR-509-3p mimics and YAP1 siRNA impair 
spheroid formation in 3D culture models of 
ovarian cancer
In ovarian cancer, compact multicellular spheroids 
are important in metastasis, which occurs primarily 
through the peritoneal fluid or ascites [35]. We used a 
magnetic levitation-based 3D culturing system [36, 37] 
and image analysis of time-course phase contrast and 
fluorescence micrographs to evaluate the impact of miR-
509-3p and YAP1 on spheroid formation in HEYA8 and 
OVCAR8 cells (Figure 5B–5F). We compared untreated 
(NT) to cells treated with a negative control (NC), 
miR-509-3p or siRNA to YAP1, starting time courses 
72 h after transfection. As we had seen for migration 
and invasion, the treatments had different effects on 
the two cell lines. For HEYA8 cells, miR-509-3p and 
siYAP1 treatments attenuated aggregation moderately 
more than NT and NC treatments (Figure 5B–5D). 
For OVCAR8 cells miR-509-3p treatment strongly 
attenuated cellular aggregation into spheroids, with treated 
cells remaining largely dispersed, while siYAP1 treatment 
attenuated aggregation at a level intermediate between NC 
and miR-509-3p treatment (Figure 5B, 5E and 5F). We 
Figure 4: YAP1 target validation, and correlation with survival and migration. (A) Relative mRNA transcript levels by 
qPCR and (B) protein levels by Western blot after miR-509-3p transfection and siRNA for YAP1, for HEYA8 (H8) and OVCAR8 (O8) cell 
lines. Error bars represent standard deviations. *, **, and *** indicate P < 0.1, 0.01 and 0.001. (C) Predicted binding sites in the YAP1 3′ 
UTR. (D) YAP1 luciferase reporter activity for the two predicted binding sites, 48 h after transfecting a miR-509-3p mimic into HEYA8 
and OVCAR8 cells. NT = no treatment. miR-NC = scrambled miR-509-3p mimic. Error bars represent standard deviations. *** indicates 
P < 0.001. (E) Yap1 immunofluorescence staining (middle panel) of non-transfected (NT) HEYA8 and OVCAR8 cells or cells transfected 
with miR-509-3p, Yap1 siRNA (siYap1) or a negative control scrambled miRNA (NC) for 72 hr. Cell nuclei were stained with DAPI (left 
panel). Scale bars represent 50 um. (F) Kaplan-Meier curves for overall patient survival for high vs. low YAP1 abundance, using TCGA 
sequencing data and a 17 RPKM threshold [20].
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confirmed that spheroid formation was also attenuated in 
SKOV3, OVCAR3, OVCAR4 and OVCAR5 cell lines, 
with the magnitude of the attenuation varying between cell 
lines (Figure 6B). We also tested miR-508-3p, miR-508-5p, 
miR-509-3p and miR-509-5p effects on spheroid formation 
(Figure S8); of these, only miR-509-3p attenuated cellular 
aggregation into spheroids in OVCAR8 cells. This is 
consistent with our results showing that, of the Xq27.3 
cluster members, miR-509-3p was the most clinically 
significant in relation to overall survival of ovarian cancer 
patients.
DISCUSSION
In the work reported here, we identified microRNA-
509-3p as a clinically significant microRNA by integrating 
functional assays and clinical outcomes with microRNA 
and RNA sequencing data from over 250 tumors from The 
Cancer Genome Atlas (TCGA) ovarian cancer cohort. We 
used in situ hybridization (ISH) to confirm the association 
of miR-509-3p with survival in an independent cohort 
of 157 ovarian cancer tumors. miR-509-3p attenuated 
cellular migration and spheroid formation in all six ovarian 
cancer cell lines tested. In ovarian cancer cell lines, our 
results established that miR-509-3p can functionally alter 
YAP1 levels, and can attenuate migration, invasion, and 
aggregation into 3D spheroids. 
miR-509-3p is expressed from a ~100-kb genomic 
cluster of miRNAs on Xq27.3. Members of this miR 
cluster have been associated with stage and survival 
in ovarian cancer, and are less abundant in omental 
metastases than in primary tumors [38–46]. In renal 
cancer, cluster members are less abundant than in 
adjacent normal tissue, and overexpression can reduce 
proliferation and migration, while  inducing apoptosis 
[47, 48]. In contrast, in melanoma, low abundance of 
cluster members is associated with impaired growth, 
invasiveness and colony formation, and with increased 
Figure 5: The effect of miR-509-3p and siYAP1 on cell migration and 3D aggregate formation for HEYA8 (left) and 
OVCAR8 (right) cells. (A) In vitro 96-well migration time-course results for miR-509-3p transfection and for siRNA for YAP1, 
in HEYA8 and OVCAR8 cells. (B) Time course evolution of spheroidal aggregation. (C, D) Phase contrast and (E, F) fluorescence 
micrographs of time-course experiments. For treated cases in (A–F), time courses start (0 hr) 72 h after transfection. NT: no treatment. NC: 
treatment with a scrambled miR-509-3p mimic.
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apoptosis [49]. Recently, miR-509-3p was confirmed to 
directly target XIAP and inhibit proliferation and increase 
sensitivity to cisplatin in chemoresistant ovarian cancer 
cells [50]. Members of the Xq27.3 miR cluster have been 
reported to be strongly anti-correlated to a multi-cancer 
‘metastasis-associated fibroblast’ gene signature [51]. 
miR-509-3p has recently been shown to target CDK2 
and to influence the cell cycle, colony formation and 
migration in human epithelial lung and cervical cancer 
cell lines [52]. Another family member, miR-506, and 
miR-200-family members, have been associated with 
EMT in a mesenchymal ovarian cancer subtype using the 
published microarray-based data [7, 43]. miR-509-3p and 
other Xq27.3 cluster miRs have recently been reported 
Figure 6: The effect of miR-509-3p and siYAP1 on migration and 3D aggregate formation for SKOV3, OVCAR3, 4 
and 5 cell lines. (A) In vitro 96-well migration time-course results for miR-509-3p transfection and siRNA for YAP1. The time courses 
start 72 h after transfection. (B) Fluorescence micrographs of time course evolution of spheroidal aggregation. NT: no treatment. NC: 
treatment with a scrambled miR-509-3p mimic.
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[53] as more abundant in a high-grade serous subtype 
(C5) that is defined by genes expressed in mesenchymal 
development [24], and less abundant in a subtype (C1) 
that has the poorest overall survival and is enriched in 
stromal genes.
Our results show that YAP1 is a direct downstream 
target of miR-509-3p, and is both a major effector of miR-
509-3p-mediated attenuation of migration and invasion, 
and an important effector in spheroid formation in ovarian 
cancer cells that contain higher levels of YAP1. YAP1, 
on 11q22, is frequently subject to copy number gains, 
mutations, and inappropriate expression in diverse types 
of cancer, and is considered an oncogene in ovarian and 
other cancers [34, 54–60]. Activation of YAP1 in ovarian 
tumors is negatively correlated with clinical outcomes and 
response to taxanes [61]. 
Curiously, while YAP1 is associated with the 
Hippo pathway, the mRNAs that were strongly inversely 
correlated to miR-509-3p in TCGA ovarian tumors were 
enriched not for Hippo pathway genes but for structural and 
regulatory components of the ECM. YAP1 is functionally 
associated with the ECM through its non-canonical, 
Hippo-independent role as a mechanotransducer, and, as a 
central effector in mechanotransduction, YAP1 influences 
how tumor cells sense and respond to the mechanical 
properties of the ECM and to their microenvironment 
[32, 33]. ECM changes have been reported to influence 
cell proliferation, differentiation, migration and invasion 
during normal development and differentiation [62], and 
mutations in mechanotransduction mediators, which are 
sensed by the cell as perturbations in ECM stiffness, have 
been associated with a number of diseases, including 
cancer [32, 33]. ECM rigidity and YAP1 activation can 
interact to maintain cancer-associated fibroblasts [63]. 
A tightly regulated balance between ECM deposition 
and turnover is critical for tissue homeostasis, and can be 
impaired in cancer cells, influencing migration, invasion 
and metastatic progression [35]. This is especially relevant 
to epithelial ovarian cancer, which primarily metastasizes 
by cells and multicellular spheroids exfoliating into the 
peritoneal fluid [35]. Multi-cellular spheroids can be 
drug resistant, due in part to the decreased penetrance of 
therapeutics to the protected interior cells [64]. Spheroid 
formation allows cancer cells to overcome anoikis, a form 
of apoptosis that can be triggered in individual cells that 
are unable to attach to other cells or to the ECM [65]. 
The model in Figure 7 summarizes our findings 
for miR-509-3p and the YAP1/ECM axis. Collectively, 
our results suggest that miR-509-3p-mediated changes 
in levels of YAP1 and ECM genes impair migration, 
invasion, and spheroid formation and so may attenuate 
metastatic progression in advanced stage ovarian cancer. 
Further, our results suggest that the direct downstream 
miR-509-3p target YAP1 is likely a critical driver of 
cellular migration and spheroid formation in ovarian 
cancers in which levels of YAP1 protein are high. We 
suggest that miR-509-3p and drugs that target the miR-
Figure 7: Model for the proposed mechanisms through which miR-509-3p alters the YAP1/ECM axis. Arrows and Tees 
indicate genes that were respectively up- and down-regulated in response to miR-509-3p (Figure S2). ECM functional gene groups are from 
[21], and names along the ECM/YAP1 axis were adapted from Figure 1 in [75]. 
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509-3p/YAP1/ECM axis may offer novel therapeutic 
opportunities in ovarian cancer, and potentially in other 
cancers. 
MATERIALS AND METHODS
Library construction, sequencing, data 
processing 
mRNA and miRNA sequencing data were generated 
using methods previously described [66]. For miRNA 
abundance we used a 5p and 3p mature strand data 
representation. 
Analysis data sets 
Analyses involving mRNA-seq and miRNA-
seq used 289 datasets present in both data types. For 
miRNA-seq, unsupervised clustering, subset analysis 
and differential abundance calculations used data for 475 
tumor samples. The hg19 (GRCh37) reference human 
genome was used for both data types. See Table S1.
miR-to-gene correlations 
As described recently [67], we calculated correlations 
for RPM data for each miRNA-seq 5p or 3p strand and each 
mRNA-seq transcript from reference-based assembly [10]. 
The P-values obtained from the Spearman correlations were 
corrected for multiple testing using the Benjamini Hochberg 
method. Corrections for multiple testing were done per 
miRNA, and a q-value < 0.05 significance threshold was 
applied. TargetScan v6.0 binding site predictions [11] were 
calculated on the full-length sequences of the predicted 
transcripts. Enriched GO process, function and cellular 
locations, and enriched KEGG pathways, were calculated 
using DAVID [68] and mgsa [69]. 
Independent component analysis, miICA 
In RPKM (mRNAs) and RPM (miRNA 5p or 
3p strand) expression matrices, genes and miRs with 
a maximum RPKM or RPM < 10 respectively were 
removed, and only samples with survival data and 
both mRNA and miRNA expression profiles were 
retained in the expression matrices (denoted Em and Emi 
respectively). For genes for which the expression matrix 
generated from reference-based assembly contains results 
for more than one splice variant, we sum the expression 
for the individual spice-variants across the samples, 
generating a matrix of total mRNA expression that 
contains 12664 mRNAs across the 283 samples. We use 
the R-function rm.outlier() to remove outlier mRNAs and 
miRNAs with a coefficient of variation g (i.e. standard 
deviation divided by mean expression) greater than 5. 
As is done when ICA is applied to expression matrices 
from microarray experiments, we log2-transformed the 
miRNA and mRNA expression matrices, substituting 
small values for zeros.
Independent component analysis (ICA) [13] 
decomposes an expression matrix (E, GxS) into a 
component matrix (C) and a mixing matrix (M), i.e. 
E CM=  or E C Mgs gi is
i
I
=
=
∑
1
 
where C is the GxI component matrix containing the 
independent components (ICs) in the columns, and M is 
the IxS mixing matrix giving the linear mixing of each 
IC in each sample. The convention is to scale the ICs so 
that in each IC the entries Cgi have a mean of zero and a 
variance of one. 
Component weights Mis measure the activity level 
of transcriptional programs, e.g. biological processes, 
in an IC across the samples. For example, when an IC 
maps to a cancer-related pathway, then this IC’s weights 
will be different in cancerous samples vs. non-cancerous 
samples. Component weights can be used to classify 
samples according to physiological, histological, or 
other features [70, 71]. Regarding gene weights Cgi, if 
one gene is inhibited by a transcriptional program while 
another is activated, then their gene weights will be 
anti-correlated, e.g. one being negative and the other 
positive. 
Before applying ICA, the number of independent 
components (ICs), I ≤ min (N,S), needs to be specified. 
To determine the optimal number of ICs to be estimated 
we used random matrix theory, as implemented in the 
EstDimRMT() R-function from the isva (v1.3) R package. 
The maximum of EstDimRMT() applied to the miRNA 
and the mRNA expression matrices, separately, was used 
as the number of ICs (I) to be estimated.
We used the default fastICA algorithm (v1.1–16) to 
first pre-whiten the expression matrix (E) by projecting 
it onto the first I principal components in the matrix 
(K). Subsequently we estimated an un-mixing matrix W 
such that C = EKW contains columns that are maximally 
independent, i.e. the independent components.
We extended the fastICA package to address genes 
and miRNAs simultaneously, i.e. to enable estimating an 
un-mixing matrix that simultaneously fulfills
C E K Wm m m=  and C E K Wmi mi mi=  
and maximizes the independence of the ICs 
contained in both Cm and Cmi. Subscripts m and mi denote 
mRNA and miRNA, respectively. The mixing matrices are 
calculated from the estimated un-mixing matrix by solving
C M E K W K Wm m m m m= ( )
−1  and 
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C M E K W K Wmi mi mi mi mi= ( )
−1
for Mm and Mmi.
For the ICs to be independent they must have a 
maximum negentropy [13, 72], i.e. the distribution of the 
entries Cgi in each IC is non-Gaussian. fastICA, and our 
modified fastICA, iteratively maximize the negentropy 
of the ICs using random seeding. Depending on the 
initial random guess for the un-mixing matrix, the ICs 
that do not represent structures in the data may converge 
to local, rather than to global maxima of negentropy. 
However, ICA is expected to always extract an IC that 
identifies structures in the data, i.e. to always converge 
to approximately the same negentropy maximum. To 
quantify this we run the modified fastICA 30 times. 
For each run, we calculate Spearman’s correlation 
coefficients between each of the original ICs and the 
ICs in the 29 other runs (algorithm adapted from [73]), 
and store the highest absolute correlation coefficient 
calculated for each IC in run r. We average the stored 
absolute correlation coefficients component-wise, take 
the average correlation coefficients as a measure for 
the stability of an IC, and order ICs according to their 
stability. We applied our modified fastICA() to the 
expression matrices containing the 283 samples that had 
survival and progression data, as well as miRNA and 
mRNA expression profiles
Following ICA, one way to identify significant 
genes in an IC is by finding genes that satisfy the 
inequality 
G SD Cgi i≥ ⋅α  
where SD|C.i| is the standard deviation of the 
absolute gene weights in IC i, and α is often set to a 
value between 2 and 3 [16]. Here we use α = 3. Because 
we are interested in the biological processes that are 
related to the survival and recurrence times, for each 
IC we determine an optimal cutoff for the component 
weights by using Cutoff Finder [20] v2.0 to divide the 
patients into good and poor survival or progression 
groups. 
We performed a pathway analysis on each IC by 
testing for overrepresentation of pathway gene-sets from 
the MsigDB (v3.0) (broadinstitute.org/gsea/msigdb/). 
Denoting the total number of genes annotated for a 
specific pathway (P) by Gp, and the number of significant 
genes in IC i that are annotated by P as Kp,I, we apply 
a hypergeometric test to test whether the probability 
P(X > Kp,i) is significant when there are N genes in total 
and Ni significant genes in IC i.
All p-values are FDR-corrected using the R function 
p.adjust.
For miR target enrichment calculations, a miR 
binding site was taken to be a 7mer seed match in the 
longest annotated Ensembl vGRCh37.p11 3′UTR. 
Statistical significance was calculated using q-values for 
a hypergeometric test. 
miR subsets that discriminate clinical outcomes 
To identify a concise set of miRNA mature strands 
whose expression was strongly associated with overall 
survival, we extracted combinatorial subsets of all mature 
strands from members of the Xq27.3 miR cluster, and from 
the miR-29 and miR-200-families, separately, and tested 
each subset for its log-rank P-value using the R survival 
package. For each of the three sets of 5p and 3p strands, 
we generated all possible subsets, and for each subset 
we separated samples into two groups using k-means 
clustering on abundance (RPM) data that we normalized 
between samples, and then again between miRNAs, 
such that the range of abundance was not a factor in the 
clustering. We tested Kaplan-Meier (KM) curves for each 
pair of sample groups for statistical significance, correcting 
log-rank P-values for multiple testing using the Benjamini 
Hochberg method. Representative subsets for which we 
displayed KM plots had a both high-ranked significant KM 
log-rank P-value and relatively large numbers of samples 
in the smaller of the two sample groups.
Cell cultures and transient transfections 
Ovarian cancer cell lines OVCAR8 and HEYA8 
were maintained in RPMI media (Life Technologies) 
supplemented with 10% heat inactivated fetal bovine 
serum (Atlanta Biologicals) and 1% of penicillin/
streptomycin. Cell lines were incubated at 37°C with 90% 
humidity and 5% CO2. miRNA mimics/YAP1 siRNA (Life 
Technologies) and negative controls (Life Technologies) 
were transiently transfected at a 20 nM concentration using 
Lipofectamine 3000 (Life Technologies) following the 
manufacturer’s recommendations. For rescue experiments, 
pCDNA Flag-Yap1/empty vector C-FLAG-pCDNA3 were 
transfected at 3.6 ug/well in a 6-well plate using FuGene 
HD (Promega) 24 hrs after miRNA transfection, following 
the manufacturer’s recommendations.
Scratch-wound migration assay 
Scratch-wound assays were performed using the 
Essen BioScience Cell Player Migration System. Seventy-
two h after transfection, cells were seeded in 96-well 
ImageLock microplates (Essen BioScience) at 35,000 
cells per well. Artificial scratch wounds were generated 
using the 96-well WoundMaker™. Each well was washed 
twice with PBS, and then overlaid with 200 μL of RPMI 
1640 medium supplemented with 10% FBS. Images were 
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acquired using the IncuCyte-FLR™ live cell imaging 
platform. Cell migration was calculated with IncuCyte’s 
automated image analysis algorithm using the Relative 
Wound Density (RWD) metric, which is defined by
RWD t w t w
c t w
( ) ( ) ( )
( ) ( )
=
−
−
100 0
0
 
where w(t) is the density of the wound region and 
c(t) is the density of the cell region at time t. Density 
was plotted as a function of time for three independent 
experiments, with error bars showing standard deviations. 
Statistical significance was determined using one-way 
ANOVA with the Tukey posthoc test (IBM SPSS Statistics 
21). Results reported in Figures 3 and 5 were from 
independent experiments in two laboratories. 
For the YAP1 overexpression rescue experiment, 
scratches were made using 200 ul pipette tips. Cells were 
washed two times by PBS and fresh media was added. 
The cell culture plates were transferred to a Biostation 
CT (Nikon) instrument programmed to take images 
every 4 h for up to 40 h. The images at different time 
points were aligned using the NIS-Element AR software. 
Scratch edges were detected and scratch area was masked 
with red color for all the images using NIS-Element AR 
software. Binary area fraction (fraction of masked area 
with red color) for each time point was measured using 
NIS-Element AR software. Area covered due to migration 
of cells after each time point was obtained by subtracting 
binary area fraction for each time point from that of initial 
time point. Average migration area for each time point was 
calculated for three biological replicates.
Matrigel invasion assay 
Cell invasion assays were performed using Matrigel-
coated 96-well microplates. Scratch-wounds were 
generated as described for the scratch-wound migration 
assay, and 50 μL of Matrigel Matrix (BD Biosciences), 
diluted to 1 mg/mL in cell culture medium, was added to 
each well. Microplates were incubated at 37°C to set the 
Matrigel, and was overlaid with 200 μL of culture medium 
24 h later. Density was plotted as a function of time for 
three independent experiments, with error bars showing 
standard error deviations.
3D culture assay 
To form three dimensional (3D) cell aggregates, 
cells, with or without miRNA/siRNA transfection, 
were incubated overnight in RPMI with 10% FBS, 
with a magnetic gold–polymer–iron oxide hydrogel 
(Nanoshuttle-PL, NS) (n3D Biosciences, Houston TX) to 
allow the attachment of NS to the cells [36, 37, 74]. 5 uM 
of CellTracker Green CMFDA Dye (Molecular Probes) 
was added to the cells and incubated for 30 minutes. The 
cells were washed with PBS, trypsinized, resuspended 
in RPMI with 10% FBS, and then magnetically levitated 
to the air-water interface for 4 hours, where they formed 
3D structures with an ECM. Next, the 3D structures were 
mechanically disrupted by pipetting, and the resulting 
suspensions of aggregates were transferred to a 96-well 
plate, where they were formed or ‘printed’ into either 
a dot or a ring shape by placing a dot or ring magnet 
‘drive’ underneath the plate for 15 minutes. Using either 
phase contrast or fluorescence, the 3D culture area was 
automatically imaged over time by an IncuCyte ZOOM 
live-cell imaging system (Essen BioSciences, Ann Arbor, 
Michigan), and the area of the dense 3D spheroidal regions 
was recorded for each well. 
Quantitative polymerase chain reaction (qPCR) 
Total RNA from cellular pellets was isolated using an 
miRNeasy Mini Kit (Qiagen) following the manufacturer’s 
instructions. Purity and RNA concentration were 
measured using a ND-100 Nanodrop spectrophotometer 
(Thermo Scientific). Reverse transcription of mRNAs 
was performed using the TaqMan Reverse Transcription 
Reagents (Invitrogen) using 300 ng of total RNA for each 
20 μL reaction. qPCR was performed using the SYBR 
Green reagent (Applied Biosystems) in a 10 μL reaction 
with 1 μL of cDNA and 0.005 nmol of primers. Reactions 
were run on a StepOnePlus Real-Time PCR system (Life 
Technologies) and analyzed using the delta-delta CT 
method. The level of 18S ribosomal RNA was used to 
normalize the relative expression of genes.
In situ hybridization 
A tissue microarray with high-grade serous ovarian 
cancer samples, as determined by a gynecologic pathologist, 
was used. Formalin-fixed paraffin-embedded tissue sections 
were dewaxed in xylene, and rehydrated through an ethanol 
dilution series. Tissue sections were digested with 15 μg/
mL proteinase K for 20 min at room temperature, were 
then loaded onto a Discovery Ultra slide staining system 
(Ventana/Roche) for in situ hybridization. The tissue 
microarray slides were incubated with a double DIG-
labeled miRCURY LNA microRNA probe (Exiqon) for 2 
h. The digoxigenin was then detected with a polyclonal anti-
DIG antibody and alkaline phosphatase-conjugated second 
antibody (Ventana) using NBT-BCIP as the substrate. We 
confirmed that ovarian tissue has very low background 
staining, using a double DIG-labeled LNA negative control 
probe (Exiqon) and the same procedure as above. 
The expression levels for miR-509-3p were 
determined as previously described [26]. In brief, 
representative images from each tissue section were 
imaged at 10 × magnification. Blinded from all clinical 
data, CellProfiler 2.0 software [75] was trained with 
negative and positive controls to establish staining 
intensity threshold levels and cell diameter parameters 
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for enumerating the number of positively stained cells at 
100 × magnification. These parameters were used to score 
all images. 
Luciferase reporter assay 
The DNA sequence, flanked by ~ 600 nucleotides, 
with the two predicted miR-509-3p target sites at -329 to 
-336 nt in the 3483-nt YAP1 3′UTR (YAP1_1: -329 bp 
to -336 bp, YAP1_2: -3084 bp to -3091bp) were PCR-
amplified from human genomic DNA and sub-cloned 
into the NotI restriction site of a psiCHECK-2 vector 
(Promega) using the Gibson Assembly Cloning Kit (New 
England Biolabs). We generated mutant clones by mutating 
the miR-509-3p seed interaction sites in the reporter 
plasmid construct, using the Q5 Site-Directed Mutagenesis 
kit (New England Biolabs) for YAP1_1 (ACCAATCA-
>ACgAtTCA) and the QuickChange II XL Site-Directed 
Mutagenesis kit (Agilent Technologies) for YAP1_2 
(ACCAATCA->gCCAAgCA). Both clones were verified 
by Sanger sequencing. 100ng of each reporter plasmid 
was transfected alone, or co-transfected with either 20 nM 
of a miR-509-3p mimic, or a scrambled negative control 
miRNA mimic, into HEYA8 and OVCAR8 cells, using 
lipofectamine 2000 (Life Technologies) at 10000 cells/
well in a 96-well plate, following the manufacturer’s 
recommended protocol. Luciferase assays were performed 
at 48 h post transfection using a Dual-Luciferase Reporter 
Assay System (Promega). Renilla luminescence signals 
were normalized by the firefly luciferase signals. Three 
replicates were performed for each assay.
Relationship of YAP1 abundance and survival 
An RPKM abundance threshold giving the most 
significant high-vs-low log-rank P-value for overall 
survival was identified with CutoffFinder v2.0 [20]. 
ECM functional gene groups 
Gene symbols for each ECM functional category 
[21] were taken from matrisome-table-Hs_CURRENT.
xlsx, which was downloaded from web.mit.edu/hyneslab/
matrisome.
Statistical significance of overlap between two 
gene lists 
P-values were calculated using a custom 
Mathematica (Wolfram Research, Champaign, IL) script 
that implemented the method described at nemates.org/
MA/progs/representation.stats.html. For example, given a 
population of npop = 21929 genes, d = 1368 predicted target 
genes for the Xq27.3 cluster members and n = 200 ECM 
glycoproteins from matrisome-table-Hs_CURRENT.xlsx 
from web.mit.edu/hyneslab/matrisome [21] had an overlap 
of x = 38 genes, for which P = 6.3E-10. 
Immunofluorescence staining
Cells were seeded onto a Falcon culture slide 
(Corning) and cultured in complete RPMI medium under 
standard cell culture conditions. Cells were fixed in 4% 
paraformaldehyde at room temperature for 15 min, then 
were permeabilized in 1 × PBS containing 0.1% Tween-100 
for 30 min at room temperature. The cells were blocked in 
a solution of 1 × PBS containing 10% normal goat serum 
and 0.1% Triton X-100 for 4 h. After being washed twice 
with 1 × PBS for 5 min each time, the cells were incubated 
overnight with a 1:200 dilution of monoclonal rabbit Yap1 
antibody (Cell Signaling Technology) in the blocking 
solution at 4°C. After being washed twice with 1 × PBS for 5 
min each time, a goat anti-rabbit IgG conjugated with Alexa 
Fluor 568 (Life Technologies) at 1:1000 in the blocking 
solution was incubated with the cells at room temperature 
for 1 hr. The cells were stained with DAPI for 5 min after 
being washed twice with 1 × PBS, and then mounted with 
ProLong Gold Antifade Mountant (Life Technologies). 
The fluorescence images were acquired using an Olympus 
imaging microscope with a 20 × objective.
Western blot
Total proteins were extracted from cellular pellets 
using protein extraction buffer (Triton X-100 1%, NaCl 
150 mM, Tris 25 mM, pH 7.6) with Complete mini 
protease inhibitors (Roche). Thirty micrograms of protein 
were run on Nupage-NOVEX Bis-Tris 4–12% gels using 
a MOPS buffer. After electrophoresis proteins were 
transferred to a PVDF membrane (Invitrogen), and the 
membranes were then blocked for 1 h at room temperature 
with 5% non-fat milk dissolved on TBS-T (50 mM Tris-
HCl, 150 mM NaCl, 0.1% Tween 20, pH 7.5). Primary 
antibodies Yap1 and GAPDH (Cell Signaling Technology) 
were added at a concentration of 1:1000 and were 
incubated overnight with the membrane at 4°C. HRP-
linked anti-rabbit secondary antibodies (Cell Signaling 
Technology) were added at a concentration of 1:10,000 
and incubated with membrane at room temperature for 
1 hr. The proteins were visualized using a Pierce ECL Plus 
chemiluminescent substrate (Thermo Scientific).
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